A response of rituximab plus lenalidomide therapy in patients with post-transplant lymphoproliferative disease and methotrexate-related lymphoproliferative disorder in the central nervous system: a case report

利妥昔单抗联合来那度胺治疗移植后淋巴增殖性疾病和甲氨蝶呤相关中枢神经系统淋巴增殖性疾病患者的疗效:病例报告

阅读:1

Abstract

BACKGROUND: Post-transplant lymphoproliferative disorder and methotrexate-related lymphoproliferative disorder are rare complications normally with unfavorable prognosis. Post-transplant lymphoproliferative disorder of the central nervous system is a rare disorder and predominantly presents as diffuse large B-cell lymphomas of non-germinal center cell origin. However, the treatment for these patients with this diagnosis has not reached a consensus. CASE 1 AND 2 PRESENTATIONS: In this case report, one patient with post-transplant lymphoproliferative disorder and another patient with methotrexate-related lymphoproliferative disorder were both diagnosed with Epstein-Barr virus-diffuse large B-cell lymphomas of primary central nervous system. The former case was a 37-year-old Han Chinese female diagnosed with post-transplant lymphoproliferative disorder of the central nervous system after a kidney transplant, and the latter case was a 61-year-old Han Chinese male diagnosed with methotrexate-related lymphoproliferative disorder after receiving methotrexate treatment for psoriasis. The initial treatment for both of them was rituximab plus lenalidomide followed by lenalidomide as maintenance for disease progression or intolerance. After the treatment, magnetic resonance imaging showed partial response or complete remission of their brain lesions. In addition, the renal function of the patient with post-transplant lymphoproliferative disorder of the central nervous system was normal, and psoriasis did not recur in the patient with methotrexate-related lymphoproliferative disorder during lenalidomide maintenance treatment. CONCLUSION: The treatment has proved to be a promising therapeutic method for post-transplant lymphoproliferative disorder of the central nervous system and methotrexate-related lymphoproliferative disorder, when the decreasing or withdrawal of immunosuppressive therapy could not achieve a satisfying outcome. Owing to the relatively small sample size, the effect of this treatment should be further investigated under a larger sample size.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。